Top Hedge Fund News, Member Posts, Hedge Fund Daily Indices and more!

5yrs ago Hedge Fund hfm.global Views: 440

The El Camino Hospital investment committee is eyeing several changes to its hedge fund portfolio, including a $5m initial allocation to Carlson Capital.

The board overseeing the $265m surplus cash portfolio is considering investing in the Black Diamond Arbitrage Fund, which would sit within its relative value portfolio.

The investment would be funded by excess cash.

Clint Carlson’s Dallas-based firm is a “well-regarded member of the hedge fund industry”, investment consultant Pavilion Advisory Group wrote in its recommendation to El Camino, which was discussed at a 13 August meeting.

Black Diamond Arbitrage runs an event-driven strategy targeting the securities of companies facing a major corporate event.

“Throughout the fund’s long track record, it has exhibited low beta to traditional equity and credit markets and notably has not experienced a calendar year with negative performance, to date,” Pavilion wrote.

“We believe the fund is a good candidate for investors looking for a merger arbitrage/special situations fund with very low market correlation run by a seasoned investment team and where the firm’s principal and employees have significant (10%) capital invested alongside external investors.”

Carlson manages $4.5bn in the event-driven strategy. Black Diamond Arbitrage was up 3.8% for the year through 30 July and returned 6.5% last year, according to performance data seen by HFM InvestHedge.

Pavilion is also reviewing El Camino’s exposures to the BlackRock 32 Capital Fund and Tiger Eye Fund and will work with staff to approve and implement any required changes, the latest board documents said, although the proposed changes were not detailed.

Mountain View, California-based El Camino had $7.9m invested in long/short US equity-focused Tiger Eye and $6.2m in the quant market-neutral BlackRock fund as of 30 June.

The hospital surplus cash plan, which has $135m dedicated to direct hedge funds, invested $4m in Moore Macro Managers Fund on 1 July, bringing its total allocation to Louis Bacon’s hedge fund to $10.7m.

That follows allocations of $3m, $2m and $5m to Bloom Tree Offshore Fund, Indus Japan Fund and Stone Milliner Macro Fund respectively, made on 1 May.

Pavilion also told El Camino at its latest meeting that it had put Lighthouse Investment Partners on watch, following the completion of the Florida FoHF’s acquisition of $8bn Mesirow Advanced Strategies (MAS) in July.

The consultant noted that although early conversations about the acquisition indicated that it made sense, a number of uncertainties around the integration process remain.

In May, HFM InvestHedge revealed that MAS senior executive duo Tom Macina and Greg Fedorinchik were not making the move to $11bn Lighthouse, although most of investment, client and operations staff were expected to do so.

The hospital’s surplus cash plan has $16.5m invested in Lighthouse and another $15.9m invested in Pointer Capital.

El Camino did not respond to requests for comment.

El Camino Hospital eyeing Carlson Capital ticket on HFM InvestHedge.


Today's Hedge Fund Headlines:

Log In for More
Access Over 250K+ Industry Headlines, Posts and Updates
Not a member yet?

Join AlphaMaven

The Premier Alternative Investment
Research and Due Diligence Platform for Investors

Free Membership for Qualified Investors and Industry Participants
  • Easily Customize Content to Match Your Investment Preferences
  • Breaking News 24/7/365
  • Daily Newsletter & Indices
  • Alternative Investment Listings & LeaderBoards
  • Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets, Presentations, Investment Mandates, Video PitchBooks & More!
  • Company Directory
  • Contact Directory
  • Member Posts & Publications
  • Alpha University Video Series to Expand Investor Knowledge
  • AUM Accelerator Program (designed for investment managers)
  • Over 450K+ Industry Headlines, Posts and Updates
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.